A Study to Explore Clinicians’ Point-Of-Care Decision-Making Process and Behavior following a Pharmacogenomics Alert


About this study

The purpose of this study is to develop a deeper understanding of a clinician’s point-of-care decision making processes following their interaction with a pharmacogenomics CDS alert.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Practicing clinician prescribers (Mayo Clinic, Rochester, MN) who receive a pharmacogenomics alert upon ordering a medication with an established clinical decision support rule in the EHR.

Exclusion Criteria: 

  • Practicing clinicians who do not experience a pharmacogenomics alert invoked by clinical decision support when prescribing medications or who do not practice at Mayo Clinic in Rochester, MN.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Carolyn Vitek, Ed.D., M.S.

Closed for enrollment

More information


Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions